Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 143 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin Pump therapy Clear all
Completed Phase 4 Interventional

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Aspart
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 5, 2026, 9:42 AM EDT
Recruiting Phase 1 Interventional

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

NCT05065372
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions
Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
Drug
Lead sponsor
Kalie Tommerdahl
Other
Eligibility
12 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

NCT04796779
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 5, 2026, 9:42 AM EDT
Withdrawn Not applicable Interventional

Embecta AID System in Adults With Type 2 Diabetes

NCT06692153
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 DM, T2DM With Inadequate Glycemic Control, T2DM (Type 2 Diabetes Mellitus), T2D, T2DM
Interventions
An AID System., Standard of Care (SC)
Device · Other
Lead sponsor
Embecta Corp.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Palo Alto, California • Walnut Creek, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery

NCT04784637
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Web Simulation Tool (WST), Behavioral Adaptation Module (BAM), Auto Titration Module (ATM), Automated Insulin Delivery (AID) System
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 5, 2026, 9:42 AM EDT
Not listed Not applicable Interventional

Real-time Continuous Glucose Monitoring

NCT03326232
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Continuous glucose monitoring
Device
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 5, 2026, 9:42 AM EDT
Active, not recruiting Phase 1 Interventional Results available

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

NCT03354390
View directory record Official record
Conditions
Kidney Cancer
Interventions
cell infusion
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

NCT04201496
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks, No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Combination Product · Device
Lead sponsor
Ananda Basu, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp

NCT02604524
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Closed-Loop Control, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
Daniel Chernavvsky, MD, CRC
Other
Eligibility
10 Years to 25 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

NCT03369067
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion
Device
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

NCT05785832
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 5, 2026, 9:42 AM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes

NCT00922649
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin Pump therapy
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • San Diego, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 5, 2026, 9:42 AM EDT
Recruiting Not applicable Interventional

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT07187479
View directory record Official record
Conditions
Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
Interventions
Physiologic Insulin Resensitization (PIR)
Other
Lead sponsor
Well Cell Global
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 5, 2026, 9:42 AM EDT
Recruiting Phase 2 Interventional

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
View directory record Official record
Conditions
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions
Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 5, 2026, 9:42 AM EDT
Terminated Not applicable Interventional Results available

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

NCT00428207
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart versus Insulin Lispro, Insulin Lispro versus Insulin Aspart
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 5, 2026, 9:42 AM EDT
Active, not recruiting Phase 3 Interventional

Bionic Pancreas in CFRD

NCT06449677
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
iLet Bionic Pancreas System (BP), Usual Care (UC)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
14 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 5, 2026, 9:42 AM EDT
Withdrawn Not applicable Interventional

Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

NCT00287456
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
Insulin Pump, Insulin, Oral Glucose Tolerance Test, Whole body Protein Turnover
Device · Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 32 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Results available

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

NCT02500979
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Early Phase 1 Interventional

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, hyaluronidase, Lispro-PH20
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

NCT01859312
View directory record Official record
Conditions
Adrenal Insufficiency, Excess Androgen, Congenital Adrenal Hyperplasia (CAH)
Interventions
Hydrocortisone (Solucortef), Insulin pump (Medtronic)
Drug · Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

NCT05325294
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed 780G System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas

NCT01762059
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bi-homonal Bionic Pancreas, Usual care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 5, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes

NCT03552523
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 5, 2026, 9:42 AM EDT